Genmab | GEN - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Amarin USD 3K 5K 2024-12
Amgen USD 95.64B 94.98B 2026-06
argenx SE USD 1000K 172K 2026-03
AstraZeneca USD 340M 144M 2026-06
Bayer EUR 675M 87M 2025-12
BioMarin Pharmaceutical USD 63.29M 48.34M 2026-06
Demant DKK 424M 26M 2026-06
Exelixis USD 23.4M 3.9M 2023-09
Fresenius Medical Care EUR 83M 4M 2026-06
Genmab DKK 139M 129M 2026-06
GlaxoSmithKline GBP 121M 46M 2026-06
GN Store Nord DKK 286M 10M 2026-06
GRIFOLS EUR 141.43M 61.28M 2025-06
Hikma Pharmaceutical USD 67M 47M 2025-12
Insmed USD 18.84M 1.24M 2026-06
Lakefront Biotherapeutics EUR 1.72M 940K 2025-09
Lonza CHF 84M 14M 2025-06
Merck EUR 137M 33M 2026-06
Novartis USD 462M 119M 2026-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR 287M 109M 2026-06
UCB EUR 49M 29M 2025-12